Xinhua Pharmaceutical: Obtained Notice of Approval for Drug Clinical Trials.

Xinhua Pharmaceuticals announcement: Recently, the company received the Approval Notice for Clinical Trial of Drug LXH-1211 Tablets issued by the National Medical Products Administration. The drug name is LXH-1211 tablets, the dosage form is tablets, with specifications of 0.5mg, 1mg, 2mg, 5mg. The drug is classified as prescription medicine, registered as Class 1 chemical drug. The approval conclusion is that according to the Drug Administration Law of the People's Republic of China and relevant regulations, the clinical trial application for LXH-1211 tablets submitted on July 10, 2025 meets the relevant requirements for drug registration and allows the drug to conduct clinical trials for pulmonary arterial hypertension.